Skip to main content
. 2023 Mar 31;29(10):1894–1905. doi: 10.1158/1078-0432.CCR-22-3136

Figure 2.

Figure 2. Event-free survival per central review and ORR in patients ≥65 years. A, The Kaplan–Meier estimate of EFS by blinded central review in patients ≥65 years. EFS was defined as the time from randomization to the earliest date of disease progression according to the Lugano classification (17), new lymphoma therapy, death from any cause, or a best response of stable disease up to and including the response on day 150 assessment after randomization, per blinded central review. Tick marks indicate patients who did not meet the criteria for an event and were censored. B, Summary of best response by blinded central review in patients ≥65 years. a In the SOC arm, 1 patient had undefined disease, and 4 did not have response assessments completed. EFS, event-free survival; PD, progressive disease; PR, partial response; SD, stable disease.

Event-free survival per central review and ORR in patients ≥65 years. A, The Kaplan–Meier estimate of EFS by blinded central review in patients ≥65 years. EFS was defined as the time from randomization to the earliest date of disease progression according to the Lugano classification (17), new lymphoma therapy, death from any cause, or a best response of stable disease up to and including the response on day 150 assessment after randomization, per blinded central review. Tick marks indicate patients who did not meet the criteria for an event and were censored. B, Summary of best response by blinded central review in patients ≥65 years. a In the SOC arm, 1 patient had undefined disease, and 4 did not have response assessments completed. EFS, event-free survival; PD, progressive disease; PR, partial response; SD, stable disease.